Anti-Inflammatory Diet Home Page...
 
Web Level1Diet.com
Subscribe to Anti-Inflammatory Diet RSS feeds...
Subscribe
Free Anti-inflammatory diet summary... Anti-inflammation diet weight loss story... 
Home Foods to Eat Foods to Avoid Exercise Supplements Weight Loss News Diabetes News Your Concerns Archived Reports

Bookmark Us: Yahoo Del.icio.us Simpy Technorati Email a friend Print

Hepatitis
Health Information Search Results

Matching Summaries of Recent
Peer Reviewed Scientific Research Reports.


Refine Your Search:

All Words Any Words
Search Again By Year -- Simply add a space, then the year you want to your search term.
 


 << Prev 20  Showing 1 to 20 of 63 Matches Next 20 >>



1. Hepatitis A: the burden among Latino children in California.
Match Strength: 6.434

OBJECTIVE: To determine the prevalence of Hepatitis A within subpopulations of southern California counties. MATERIAL AND METHODS: Age and race/ethnic-specific hepatitis A rates were derived from the California Department of Health Services Surveillance and Statistics Section for 1996-2001 and from demographic data of the California Department of Finance. RESULTS: 2.3 million Latino children (aged 0-14 years) in five southern California counties had a rate of 31.1 cases per 100,000, five times higher than the non-Hispanic white rate. CONCLUSION: The CDC Advisory Committee on Immunization ... Read More »
» Published in Salud Publica Mex. 2005 Nov-Dec;47(6):396-401.

2. The patient experience of treatment for hepatitis C.
Match Strength: 6.348

This study has used qualitative hermeneutics to explore the patient's experience of treatment for hepatitis C. Hepatitis C treatment may pose numerous physical and emotional challenges. There is a need to understand the experience from a holistic nursing perspective in order to facilitate the patient's well-being. Individuals undergoing combination treatment for hepatitis C participated in a hermeneutic dialogue, which provided the investigators with an emic perspective. Dialogue content, reflection, and preunderstanding were hermeneutically analyzed. Similar treatment experiences elicited ... Read More »
» Published in Gastroenterol Nurs. 2006 Jul-Aug;29(4):309-15.

3. Successful treatment of hepatitis B virus infection with Lamivudine after heart transplantation.
Match Strength: 6.203

Patients with hepatitis B virus (HBV) infection have a higher morbidity and mortality after heart transplantation (HT). HBV infection is endemic in Taiwan. We studied the effect of lamivudine treatment of HBV infection after HT. From July 1987 to July 2005, 252 patients underwent HT. All recipients and donors underwent routine screening of hepatitis B surface antigen (HBsAg), hepatitis B e antigen, antibody to hepatitis B surface antigen, antibody to hepatitis B core antigen, antibody to hepatitis B e antigen, and an alanine aminotransferase (ALT) level before HT. When ALT was two times ... Read More »
» Published in Transplant Proc. 2006 Sep;38(7):2138-40.

4. Detection of SEN virus in the general population and different risk groups in Slovakia.
Match Strength: 5.884

Sera of 426 adult persons were examined to assess the prevalence of SEN virus (SENV) infection in Slovakia and to determine the importance of different risk factors for parenteral transmission. SENV prevalence was determined by the PCR method using primers of SENV-D and SENV-H strains. Positive results were found in 10 of 37 patients with acute hepatitis of unknown etiology, 7 of 38 with acute hepatitis B, 17 of 44 with chronic hepatitis B, 29 of 102 with chronic hepatitis C, 36 of 72 hemodialysis patients, 2 of 33 health care workers and 24 of 100 persons from the control group. The highest ... Read More »
» Published in Folia Microbiol (Praha). 2006;51(3):223-8.

5. Randomized, double-blind, placebo-controlled trial of bovine lactoferrin in patients with chronic hepatitis C.
Match Strength: 5.593

Several studies have suggested that lactoferrin administration may decrease the serum level of hepatitis C virus (HCV) RNA in patients with chronic hepatitis C. The aim of the present study was to confirm the efficacy of orally administered bovine lactoferrin (bLF) in patients with chronic hepatitis C. The patients with chronic hepatitis C randomly received either oral bLF at a dose of 1.8 g daily for 12 weeks, or an oral placebo. The primary endpoint was the virologic response, defined as a 50% or greater decrease in serum HCV RNA level at 12 weeks compared with the baseline. The secondary ... Read More »
» Published in Cancer Sci. 2006 Oct;97(10):1105-10.

6. Hepatitis A virus infection in people of South Asian origin in England and Wales: analysis of laboratory reports between 1992 and 2004.
Match Strength: 5.542

The aim of the study was to determine whether rates of hepatitis A infection are higher in people of South Asian origin compared to the general population, to look for evidence of spread to the general population, and to identify ways to improve preventive strategies. Routine laboratory reports of hepatitis A infection in England and Wales in 1992-2004 were analysed. Study participants were patients with confirmed hepatitis A infection reported to the Health Protection Agency by the diagnosing laboratory. Nam Pehchan software was used to identify patients of South Asian ethnicity. Main outcome ... Read More »
» Published in Epidemiol Infect. 2006 Sep 26;:1-6

7. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Match Strength: 5.462

OBJECTIVE: At present sequential monotherapy for chronic hepatitis B with hepatitis B virus (HBV)-polymerase inhibitors is clinical practice. It is unknown to date whether combination therapy with lamivudine plus tenofovir could be superior to sequential therapy with tenofovir after the occurrence of lamivudine resistance. METHODS: We conducted a multicenter, 1: 2 matched pair analysis comparing patients with HBV/HIV-coinfection starting an antiretroviral regimen including tenofovir plus lamivudine with patients who had highly replicative, lamivudine resistant HBe-antigen positive chronic ... Read More »
» Published in AIDS. 2006 Oct 3;20(15):1951-4.

8. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization.
Match Strength: 5.337

OBJECTIVES: To evaluate the impact of the universal hepatitis B (HB) vaccination programme on the prevalence of hepatitis B surface antigen (HBsAg) carriers and immunity to HB virus infection among children <18 years and to determine the HB seroprevalence in the Thai population. METHODS: We enrolled people in four provinces, including Chiangrai, Udon Thani, Chonburi and Nakhon Si Thammarat to geographically represent populations in the North, Northeast, Center and South of the country respectively. Serology for HBsAg, anti-hepatitis B surface (anti-HBs), and anti-hepatitis B core (anti-HBc) ... Read More »
» Published in Trop Med Int Health. 2006 Oct;11(10):1496-502.

9. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations.
Match Strength: 5.254

OBJECTIVES: To assess the efficacy of sequential treatment with lamivudine and interferon-alpha monotherapies in Chinese patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. METHODS: One hundred and sixty-two patients with HBeAg-negative chronic hepatitis B were included in this study. Ninety-eight were treated with lamivudine alone (100 mg per day) for 48 weeks (group B). Sixty-four were treated with lamivudine alone (100 mg per day) for 20 weeks, then combined with interferon-alpha-2b (5 million units three times per week) for 4 weeks and then treated for another 24 ... Read More »
» Published in J Antimicrob Chemother. 2006 Nov;58(5):1031-5. Epub 2006 Sep 19.

10. Outcomes of hepatitis B virus recurrence after liver transplantation.
Match Strength: 5.222

The introduction of high doses of hepatitis B immune globulin (HBIG) and lamivudine for liver transplantation (OLT) prophylaxis has reduced the risk of hepatitis B recurrence and improved the survival of patients transplanted for hepatitis B virus (HBV)-related liver disease. But, posttransplant prophylaxis strategies to treat the recurrence of HBV have not yet been standardized. We analyzed 23 patients with HBV recurrence among 340 HBV-associated liver transplants performed from September 1996 to April 2004 (6.7%). Nine patients underwent deceased donor OLT and 14, living donor OLT. Mean ... Read More »
» Published in Transplant Proc. 2006 Sep;38(7):2123-4.

11. Peer referral for HIV case-finding among men who have sex with men.
Match Strength: 5.104

OBJECTIVE: To evaluate the effectiveness and cost-effectiveness of a health department-based peer referral program for identifying previously undiagnosed cases of HIV among men who have sex with men (MSM). DESIGN AND METHODS: Between 2002 and 2005, 283 MSM peer recruiters were enrolled in a public health program in King County, Washington, USA. Peer recruiters were enrolled from a sexually transmitted disease (STD) clinic, an HIV clinic, via media advertisements and through collaboration with community-based organizations (CBO). The peer recruiters underwent a brief training and were then paid ... Read More »
» Published in AIDS. 2006 Oct 3;20(15):1961-8.

12. Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses.
Match Strength: 5.026

The liver disease characteristic of alcohol dependence encompasses three main related entities: steatosis, alcoholic hepatitis, and cirrhosis. Alcoholic cirrhosis is a leading cause of global morbidity and mortality. Alcohol intake among injecting drug users is a major contributor to transmission of viral infections, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C viruses (HCV). HIV and HCV coinfected patients develop liver diseases earlier and more severely than the monoinfected individuals, including hepatocellular carcinoma. Interactions exist between ... Read More »
» Published in Subst Use Misuse. 2006;41(10-12):1395-463.

13. Phenotypic and functional status of intrahepatic T cells in chronic hepatitis C.
Match Strength: 4.921

Polychromatic flow-cytometric assays were used to analyze paired intrahepatic and peripheral lymphocyte samples from 37 patients with chronic hepatitis C. Compared with peripheral cells, intrahepatic T cells were selectively enriched with CD45RO+ memory T cells but had a lower percentage of CD4+ T cells expressing the differentiation markers CD27 and CD28. The percentage of intrahepatic CD45RO+ and CD28+ T cells correlated with the degree of liver inflammation, which suggests that memory T cells at relatively early stages of differentiation are directly involved in liver inflammation. Despite ... Read More »
» Published in J Infect Dis. 2006 Oct 15;194(8):1068-77. Epub 2006 Sep 15.

14. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2'-C-methylcytidine, the active component of valopicitabine.
Match Strength: 4.647

Ribavirin antagonizes the in vitro anti-hepatitis C virus (HCV) activity of the pyrimidine nucleoside analogue 2'-C-methylcytidine, the active component of the experimental anti-HCV drug valopicitabine. In contrast, the combination of ribavirin with either the purine nucleoside analogue 2'-C-methyladenosine or the HCV protease inhibitor VX-950 resulted in an additive antiviral activity. These findings may have implications when planning clinical studies with valopicitabine. Publication Types: Research Support, Non-U.S. Gov ... Read More »
» Published in Antimicrob Agents Chemother. 2006 Oct;50(10):3444-6.

15. The status of liver transplantation for hepatitis C.
Match Strength: 4.547

The hepatitis C virus (HCV) infects 3% of the world's population, or approximately 170 million people. Most of those acutely infected progress to chronic infection and are unresponsive to existing antiviral treatment. Over a 20-year period, chronic HCV infection leads to cirrhosis and the sequelae of end-stage liver disease, including hepatic encephalopathy, ascites, variceal haemorrhage and hepatocellular carcinoma. Orthotopic liver transplantation (OLT) is the optimal treatment for decompensated HCV cirrhosis, but is limited by organ availability and universal graft reinfection. This review ... Read More »
» Published in Expert Opin Biol Ther. 2006 Oct;6(10):993-1002.

16. Interferon and ribavirin treatment results of patients with HBV-HCV co-infection cured of childhood malignancies.
Match Strength: 4.486

OBJECTIVES: We aimed to investigate the virological and clinical characteristics and the results of combination therapy in six oncology patients with hepatitis B virus (HBV)-hepatitis C virus (HCV) co-infection. METHOD: Six patients (five male and one female; age range 8-14 years), diagnosed with HBV-HCV infections during follow-up at the oncology outpatient clinic during 2000-2001 were included in the study. They had received an average of 25.8 units of blood by transfusion per patient during their treatment for malignancies. Positive serological HBV indicators were determined 20-40 months ... Read More »
» Published in Int J Infect Dis. 2006 Nov;10(6):453-7. Epub 2006 Sep 26.

17. Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment.
Match Strength: 4.428

OBJECTIVES: To evaluate the alterations of serum procalcitonin (PCT) levels in patients with chronic hepatitis C during pegylated interferon-alpha (PEG-IFNa) plus ribavirin (RIB) treatment and to correlate them with clinical and virological outcomes. STUDY DESIGN: Fifty-two consecutive patients (29 males, age=41.2+/-14.7 years) with chronic HCV-related liver disease (six cirrhotics) were evaluated for PCT levels at baseline and during the treatment course (at week 12, 24, 48 and 72) with PEG-IFNa plus RIB. Sustained virological response (SVR) was confirmed by undetectable serum HCV-RNA at the ... Read More »
» Published in J Clin Virol. 2006 Dec;37(4):329-31. Epub 2006 Sep 25.

18. High and persistent excretion of hepatitis A virus in immunocompetent patients.
Match Strength: 4.422

The duration and level of virus excretion in blood and faeces of patients with hepatitis A virus (HAV) infection were studied in relation to levels of alanine aminotransferase (ALT), disease severity and HAV genotype. Clinical data, blood and faeces were collected from 27 patients with acute hepatitis A (median age: 33 years) for a maximum of 26 weeks. Single blood donations from 55 other patients with acute HAV (median age: 32 years) were also used. Virus loads were quantified by competitive nested RT-PCR. HAV was excreted in faeces for a median period of 81 days after disease onset, with 50% ... Read More »
» Published in J Med Virol. 2006 Nov;78(11):1398-405.

19. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein.
Match Strength: 4.239

The progression of chronic hepatitis B (CHB) is related to fibrosis and to the emergence of intrahepatic anomalous vascular structures. Hepatitis B virus (HBV) X protein transactivator (HBx) may play a significant role in both processes. To analyze how HBV induces vascular growth and remodeling in vivo, we assessed the expression of angiopoietin-2 (Ang2) in liver biopsies from CHB patients by reverse transcriptase-polymerase chain reaction, Western blotting, and immunohistochemistry because of the relevant role of Ang2 in vascular development, remodeling, and tumor promotion. In addition, we ... Read More »
» Published in Am J Pathol. 2006 Oct;169(4):1215-22.

20. The risk of transfusion-acquired hepatitis-C virus infection among blood donors in Port Harcourt: the question of blood safety in Nigeria.
Match Strength: 4.220

OBJECTIVE: This study was undertaken to establish the sero-epidemology of Hepatitis C Virus (HCV) antibodies among blood donors in Port Harcourt, Nigeria. METHODS: One Thousand Five Hundred consecutive blood donors presenting to the blood transfusion unit of the University of Port Harcourt Teaching Hospital between January and April, 2003 comprising of 1481 males and 19 females were screened for hepatitis C antibodies using the commercially available Clinotech anti-HCV test strips. All initially positive samples were subsequently tested using a second-generation Trinity Biotec enzyme linked ... Read More »
» Published in Niger J Clin Pract. 2006 Jun;9(1):18-21.

 << Prev 20  Showing results 1 to 20 of 63 Next 20 >>




* All information on Level1Diet.com is for educational purposes only. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Before changing your diet, or adding supplements to your diet, or beginning an exercise program, everyone should consult a qualified and licensed health practitioner; a physician, dietician or similar professional.



spacer spacer
spacer
Level1Diet.com foods to eat...
   


DO YOU KNOW ?
Over 1,532 new health studies are published every day ― 559,288 per year. Join our weekly update program to stay informed...
spacer

spacer
» About Health Updates


spacer

HAVE WE
HELPED YOU?

Donate $5 or $10
to help us promote
anti-inflammatory health.


spacer
Bigger Font Size Smaller Font Size Left Align Justify Align Right Align Bookmark This Page
spacer
Search 3.1 Million
Health Studies


» List of 4,000+ Diseases
spacer
   

spacer




Subscribe to
Level1Diet.com
Health Reports


Add to Google Reader or Homepage
Subscribe in NewsGator Online
Subscribe in Bloglines
Add to Excite MIX
Add to netvibes
Add to fwicki
Add to My AOL
Add to The Free Dictionary



About Us Contact Us Privacy Free Newsletter Health FAQs Terms of Use

 Subscribe in a reader

© 2010 Level1Diet.com, All Rights Reserved.     Contact:

Replace omega-6 vegetable oils with omega-9 olive oil... Eat oily fish like tuna, sardines, anchovy, salmon, herring... Beans, lentils, peas add fiber... Nine or more 3-ounce servings of fruits or vegetables per day...